|
Salomon D S, Brandt T, Ciardiello F. Epidermal growth factor-related peptides and their receptors in human malignancies [J]. Critical Reviews in Oncology/Hematology, 1995(3):183.
|
|
Fukuoka M, Yano S, Giaccone G. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J]. Journal of Clinical Oncology, 2003.2237.
|
|
Kris M G, Natale R B, Herbst R S. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer [J]. Journal of the American Medical Association, 2003.2149.
|
|
Thatcher N, Chang A, Parikh P. ISEL:A phase Ⅲ Ⅲ survival study oomparing gefitinib (Iressa) plus best supportive care (BSC) with placebo plus BSC in patients with advanced non small cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens [A]. Spain:Barcelona, 2005.
|
|
Lynch T J, Bell D W, Sordella R. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib [J]. New England Journal of Medicine, 2004.2129.
|
|
姜 斌, 朱冠山, 刘 峰. 中国人非小细胞肺癌EGFR基因突变的研究 [J]. 上海第二医科大学学报, 2005, (11):1148.doi: 10.3969/j.issn.1674-8115.2005.11.017.
|
|
Mok T S, Wu Y L, Thongprasert S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma [J]. New England Journal of Medicine, 2009, (10):947.
|
|
Zhou C C, Wu Y L, Chen G. Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase Ⅲ, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut +) advanced non-small cell lung cancer (NSCLC) [J]. Journal of Clinical Oncology, 2011, (suppl):abstr7520.
|
|
Gridelli C, Ciardiello F, Feld R. International multicenter randomized phase Ⅲ study of first-line erlotinib (E)followed by second-line cisplatin plus gemcitabine (CG)versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC):The TORCH trial [J]. Journal of Clinical Oncology, 2010, (15s):abstr7508.
|
|
Kabbinavar F F, Miller V A, Johnson B E. Overall survival (OS) in ATLAS, a phase Ⅲb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) [J]. Journal of Clinical Oncology, 2010, (15s):abstr7526.
|
|
Cappuzzo F, Ciuleanu T, Stelmarkh L. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer:a multicentre, randomised, placebo-controlled phase 3 study [J]. Lancet Oncology, 2010(6):521.
|
|
Kim E S, Hirsh E S, Mok V. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer(INTEREST):a randomised phase Ⅲ trial [J]. Lancet, 2008, (9652):1809.
|
|
Rossi D, Dennetta D, Ugolini M. Activity and safety of erlotinib as second-and third-line treatment in elderly patients with advanced non-small cell lung cancer:a phase Ⅱ trial [J]. Target Oncol, 2010(4):231.
|
|
Fan W C, Yu C J, Tsai C M. Different efficacies of erlotinib and gefitinib in Taiwanese patients with advanced non-small cell lung cancer:a retrospective multicenter study [J]. JOURNAL OF THORACIC ONCOLOGY, 2011(1):148.
|
|
GiacconeG, Herbst RS, Manegold C. Gefitinibincombination with gemcitabine and cisplatin in advanced non small cell lung cancer:a p hase Ⅲ trial INTACT1 [J]. Journal of Clinical Oncology, 2004(5):7772.
|
|
Herbst R S, Giaccone G, Schillcr J H. Gefitinibin combination with paclitaxel and carboplatin in advanced non small cell lung cancer:a phase Ⅲ trial INTACT2 [J]. Journal of Clinical Oncology, 2004(5):785.
|
|
Scagliotti G, Novello S, Von Pawel J. Phase Ⅲ study of carboplatin and paclitaxel alone or with soratenib in advanced non-small-cell lung cancer [J]. Journal of Clinical Oncology, 2010, (11):1810.
|
|
Stinchcombe T E, Morris D E, Lee C B. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose thee-dimension conformal thoracic radiotherapy(74GY) with concurrent carboplatin, paclitaxel, and gefitibib in unresectable stage ⅢA and stage ⅢB nonsmall cell lung cancer [J]. JOURNAL OF THORACIC ONCOLOGY, 2008(3):250.
|
|
Kelly K, Chansky K, Gaspar LE. Phase Ⅲ trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage Ⅲ non-small-cell lung cancer:SWOG S0023 [J]. Journal of Clinical Oncology, 2008, (15):2450.
|
|
Herbst R S, Johnson D H, Mininberg E. Phase Ⅰ/Ⅱ Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non Small-Cell Lung Cancer [J]. Journal of Clinical Oncology, 2005, (11):2544.
|
|
Scagliotti G, Vynnychenko I, IchinoseY. An international, randomized, pla(c)ebo-controlled, double-blind phase Ⅲ study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) [J]. Journal of Clinical Oncology, 2011, (suppl, abstr LBA7512).
|
|
Turke A B, Zejnullahu K, Wu Y L. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC [J]. Cancer Cells, 2010(1):77.
|
|
SchillerJ H, AkerleyW L, BruggerW. Results from ARQ 197-209:a global randomized placebo-controlled phase Ⅱ clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitornaive patients with locally advanced or metastatic non-small cell lung ca ncer(NSCLC) [J]. Journal of Clinical Oncology, 2010.18s(suppl, abstrLBA7502.
|
|
Spigel D, Ervin T, Rarnlau R. Randomized multicenter double-blind placebo controlled phase Ⅱ study evaluating MetMAb, an antibody to met receptor, in combination with erlotinib, in patients with advanced non-small cell lung cancer [J]. Annals of Oncology, 2010, (Suppl 8):Abstr.LBA15.
|
|
Koivunen J P, Mermel C, Zejnullahu K. EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer [J]. Clinical Cancer Research, 2008, (13):4275.
|
|
Zhang X, Zhang S, Yang X. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression [J]. Molecular Cancer Therapeutics, 2010.188.
|
|
Bang Y, Kwak EL, Shaw A. Clinical activity of the oral ALK inhibitor, Crizotinib (PF-02341066), in patients with ALK-positive non-small cell lung cancer [J]. Journal of Clinical Oncology, 2010.18s(suppl, abstr3).
|
|
Yang C, Hirsh V, Cadranel J. Phase Ⅱb/Ⅲ doubleblind randomized trial of BIBW 2992, an irreversiblc, dual inhibitor of EGFR and HER2 plus best supportive carc (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX-Lung1):A prelimirary report [J]. Journal of Clinical Oncology, 2009.15s(suppl, abstr8062).
|
|
Metro G, Crinò L. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer [J]. Expert Review of Anticancer Therapy, 2011(5):673.
|
下载:
苏公网安备 32100302010246号
